These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 5139499)

  • 21. Syntheses of anticancerous substances. Syntheses and study of the toxicity of some di-(beta chloroethyl)-amides with N-(O-nitrobenzoyl)-amino acid supports.
    Sunel V; Ciugureanu C; Ungureanu M
    Rev Med Chir Soc Med Nat Iasi; 1993; 97(2):273-9. PubMed ID: 7997672
    [No Abstract]   [Full Text] [Related]  

  • 22. A comparative study with three alkylating agents: mechlorethamine, cyclophosphamide, and uracil mustard.
    GOLD GL; SALVIN LG; SHNIDER BI
    Cancer Chemother Rep; 1962 Feb; 16():417-9. PubMed ID: 13899670
    [No Abstract]   [Full Text] [Related]  

  • 23. Utilization of newborn mice in the bioassay of chemical carcinogens.
    Gargus JL; Paynter OE; Reese WH
    Toxicol Appl Pharmacol; 1969 Nov; 15(3):552-9. PubMed ID: 5353820
    [No Abstract]   [Full Text] [Related]  

  • 24. [Effect of lofenal on rat embryogenesis].
    Pavilonis SV; Zhukene IaV; Didzhiapetrene IaK; Grazhialene GIu
    Eksp Onkol; 1984; 6(3):66-9. PubMed ID: 6499744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The electrophoretic mobility of rat-blood erythrocytes following the administration of Endoxan or nitrogen mustard compounds].
    Rauen HM; Golovinsky E; Norpoth K
    Klin Wochenschr; 1968 Mar; 46(5):276-7. PubMed ID: 5697859
    [No Abstract]   [Full Text] [Related]  

  • 26. Synergistic effects of bis(3-methylsulfonyloxypropyl)-amine toluenesulfonate (864-T) with 6-mercaptopurine and other antitumor agents.
    Imamura H; Ikegami K; Okumoto T
    Gan; 1973 Oct; 64(5):427-31. PubMed ID: 4358730
    [No Abstract]   [Full Text] [Related]  

  • 27. Phenester (NSC-116 785): convulsant effects in the dog of an alkylating agent with antitumor activity.
    Schaeppi U; Thompson GR; Fleischman RW; Stadnicki S; Phelan R; Jliewski V; Cooney DA; Davis RD
    Toxicol Appl Pharmacol; 1971 Apr; 18(4):841-50. PubMed ID: 5570236
    [No Abstract]   [Full Text] [Related]  

  • 28. Mechanism of cure of large plasma cell tumors.
    Whisson ME; Connors TA; Jeney A
    Arch Immunol Ther Exp (Warsz); 1966; 14(6):825-31. PubMed ID: 5958003
    [No Abstract]   [Full Text] [Related]  

  • 29. A comparison between the hematological side effects of cyclophosphamide and nitrogen mustard.
    NISSEN-MEYER R; HOST H
    Cancer Chemother Rep; 1960 Nov; 9():51-5. PubMed ID: 13729268
    [No Abstract]   [Full Text] [Related]  

  • 30. Cytogenetic toxicity of cyclophosphamide and its metabolites in vitro.
    Au W; Sokova OI; Kopnin B; Arrighi FE
    Cytogenet Cell Genet; 1980; 26(2-4):108-16. PubMed ID: 7389408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma cell tumors in experimental chemotherapy: consequence of dose variation on host survival and paraprotein synthesis.
    Teller MN; Bowie M; Stock CC
    J Natl Cancer Inst; 1970 Dec; 45(6):1197-203. PubMed ID: 5488064
    [No Abstract]   [Full Text] [Related]  

  • 32. Antineoplastic activity and toxicity of some alkylating cytostatics (cyclophosphamide, CCNU, cytostasan) encapsulated in liposomes in different murine tumour models.
    Fichtner I; Arndt D; Reszka R
    J Microencapsul; 1986; 3(2):77-87. PubMed ID: 3508181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synergistic lethal action of alkylating agents and sodium pentobarbital in the mouse.
    Munson AE; Rose WC; Bradley SG
    Pharmacology; 1974; 11(4):231-40. PubMed ID: 4218647
    [No Abstract]   [Full Text] [Related]  

  • 34. EXPERIMENTAL CHEMOTHERAPY STUDIES. IV. THE PROTECTIVE ACTION OF MERCAPTOALKYLAMINES AGAINST ALKYLATING AGENTS.
    RUTMAN RJ; LEWIS FS; PRICE CC
    Cancer Res; 1964 May; 24():626-33. PubMed ID: 14188465
    [No Abstract]   [Full Text] [Related]  

  • 35. Studies on 4-hydroperoxycyclophosphamide (NSC-181815): a simple preparation method and its application for the synthesis of a new class of "activated" sulfur-containing cyclophosphamide (NSC-26271) derivatives.
    Peter G; Wagner T; Hohorst HJ
    Cancer Treat Rep; 1976 Apr; 60(4):429-35. PubMed ID: 1277218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. On the neurotoxic effects induced by alkylating agents.
    Donelli MG; Rosso R; Garattini S
    J Pharm Pharmacol; 1966 Nov; 18(11):760-2. PubMed ID: 4382059
    [No Abstract]   [Full Text] [Related]  

  • 37. Toxicity of the alkylating agent bendamustin.
    Horn U; Härtl A; Güttner J; Hoffmann H
    Arch Toxicol Suppl; 1985; 8():504-6. PubMed ID: 3868382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potentiating effects of caffeine on teratogenicity of alkylating agents in mice.
    Fujii T; Nakatsuka T
    Teratology; 1983 Aug; 28(1):29-33. PubMed ID: 6415842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical toxicologic study of cyclohexylamine salt of N,N-bis(2-chlorethyl)phosphorodiamidic acid (NSC-69945; OMF-59).
    Nathanson L; Hall TC; Rutenberg A; Shadduck RK
    Cancer Chemother Rep; 1967 Feb; 51(1):35-9. PubMed ID: 6039662
    [No Abstract]   [Full Text] [Related]  

  • 40. [Testing of Rapostan for teratogenic effect].
    Szirmai E
    Pharmazie; 1967 Sep; 22(9):533. PubMed ID: 5599156
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.